Gene Therapy and Gene Editing in Type 1 Diabetes: CRISPR-Based β-Cell Replacement and Treg Immune Modulation...

Area of Science:

• Immunology
• Genetics
• Endocrinology

Background:

• Type 1 diabetes mellitus (T1DM) is an autoimmune disease causing pancreatic beta-cell destruction, necessitating lifelong insulin therapy.
• Current treatments manage symptoms but do not prevent diabetes complications, highlighting the need for curative strategies.
• Gene therapy and gene editing present novel approaches for T1DM, aiming to restore beta-cell function and achieve remission.

Purpose of the Study:

• To review the basic science and clinical evidence for gene-based T1DM therapies.
• To synthesize findings from key clinical trials investigating immune modulation and beta-cell replacement strategies.
• To identify challenges and future directions in the development of curative T1DM treatments.

Main Methods:

• Literature review synthesizing basic science and clinical trial data.
• Focus on five specific clinical protocols (NCT03162237, NCT05210530, NCT05241444, NCT05565248, NCT06938334).
• Analysis of strategies including immune modulation and beta-cell replacement.

Main Results:

• Gene therapy approaches include immune modulation (e.g., PD-L1, FOXP3) and beta-cell replacement (e.g., CRISPR-edited progenitors, xenotransplantation).
• Early clinical trials indicate feasibility and safety, but long-term efficacy, durability, and scalability require further investigation.
• Key challenges involve CRISPR off-target effects, insertional mutagenesis, xenotransplantation safety, and balancing immune tolerance.

Conclusions:

• Gene-based therapies represent a shift from insulin replacement to potential T1DM cures.
• Significant translational hurdles remain before these curative interventions can be widely applied clinically.
• Future research should focus on combination therapies, personalized medicine, and advanced gene-editing tools.